Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

JME Commentaries
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Table of contents

February 2017 - Volume 43 - 2

Journal of Medical Ethics: 43 (2)

Introduction

Paper: The benefit/risk ratio challenge in clinical research, and the case of HIV cure: an introduction (23 May, 2016)
Nir Eyal

Background

Paper: Why cure, why now? (7 June, 2016)
Daniel R Kuritzkes
Improving on effective antiretroviral therapy: how good will a cure have to be? (5 December, 2016)
Kenneth A Freedberg, Paul E Sax
Paper: How to keep high-risk studies ethical: classifying candidate solutions (9 June, 2016)
Nir Eyal

Risks

Paper: First-in-human HIV-remission studies: reducing and justifying risk (3 May, 2016)
Rebecca Dresser
Paper: When to start paediatric testing of the adult HIV cure research agenda? (3 June, 2016)
Seema K Shah
Paper: Risk and radical uncertainty in HIV research (26 September, 2016)
Caspar Hare

Benefits to participants

Paper: Why high-risk, non-expected-utility-maximising gambles can be rational and beneficial: the case of HIV cure studies (30 June, 2016)
Lara Buchak
Paper: For love and money: the need to rethink benefits in HIV cure studies (18 May, 2016)
Emily Largent
Paper: An activist's argument that participant values should guide risk–benefit ratio calculations in HIV cure research (6 January, 2017)
David Evans

Benefits to nonparticipants

Paper: Must research benefit human subjects if it is to be permissible? (29 August, 2016)
Daniel Wikler
Paper: The social value of candidate HIV cures: actualism versus possibilism (8 July, 2016)
Regina Brown, Nicholas Greig Evans
Paper: Contractualist reasoning, HIV cure clinical trials, and the moral (ir)relevance of the risk/benefit ratio (2 September, 2016)
Rahul Kumar
Paper: The morality of risks in research: reflections on Kumar (19 September, 2016)
F M Kamm

Afterword

Afterword: returning to philosophical foundations in research ethics (27 June, 2016)
Nir Eyal

Issue Information